DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization
Theranostics · 2025
DOI: 10.7150/thno.102730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Zhao Deng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Drug Resistance, Neoplasm, Glycolysis, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale
Bladder cancer (BLCA), one of the most lethal urological tumors, exhibits high rates of recurrence and chemoresistance, particularly to gemcitabine (GEM). Understanding the mechanisms of GEM resistance is crucial for improving therapeutic outcomes. Our study investigates the role of DLGAP5 in promoting GEM resistance through modulation of glycolysis and MYC protein stability in BLCA cells.
Methods
We utilized various BLCA cell lines and clinical tissue samples to analyze the impact of DLGAP5 on GEM resistance. Through biochemical assays, protein interaction studies, and gene expression analyses, we examined how DLGAP5 interacts with USP11 and MYC, assessed the effects on MYC deubiquitination and stability. The influence of these interactions on glycolytic activity and GEM resistance was also evaluated via mouse subcutaneous xenograft model and spontaneous BLCA model.
Results
Our findings indicate that DLGAP5 enhances GEM resistance by stabilizing MYC protein via deubiquitination, a process mediated by USP11. DLGAP5 was found to facilitate the interaction between USP11 and MYC, promoting MYC-driven transcription of DLGAP5 itself, thereby creating a positive feedback loop. This loop leads to sustained MYC accumulation and increased glycolytic activity, contributing to GEM resistance in BLCA cells.
Conclusion
The study highlights the critical role of DLGAP5 in regulating MYC protein stability and suggests that disrupting the DLGAP5-USP11-MYC axis may provide a novel therapeutic approach to overcome GEM resistance in BLCA. DLGAP5 represents a potential target for therapeutic intervention aimed at mitigating chemoresistance in bladder cancer BLCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Hubei Key Laboratory of Urological Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Biological Repositories, Human Genetic Resource Preservation Center of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Euler Technology, ZGC Life Sciences Park, Beijing, China.
- Center for Quantitative Biology, School of Life Sciences, Peking University, Beijing, China.
Zitieren
APA
Deng, Z., Zhou, F., Li, M., Jin, W., Yu, J., Wang, G., Qian, K., Ju, L., Zhang, Y., Xiao, Y., & Wang, X. (2025). DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization. Theranostics. https://doi.org/10.7150/thno.102730
Vancouver
Deng Z, Zhou F, Li M, Jin W, Yu J, Wang G, et al. DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization. Theranostics. 2025. doi:10.7150/thno.102730
BibTeX
@article{Deng2025,
author = {Deng, Zhao and Zhou, Fenfang and Li, Mingxing and Jin, Wan and Yu, Jingtian and Wang, Gang and Qian, Kaiyu and Ju, Lingao and Zhang, Yi and Xiao, Yu and Wang, Xinghuan},
title = {DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization},
journal = {Theranostics},
year = {2025},
doi = {10.7150/thno.102730}
}
EUVIMED